KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $641000.0.

  • Xenon Pharmaceuticals' Depreciation & Amortization (CF) fell 389.81% to $641000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 10537.55%. This contributed to the annual value of $2.6 million for FY2024, which is 2421.15% up from last year.
  • Xenon Pharmaceuticals' Depreciation & Amortization (CF) amounted to $641000.0 in Q3 2025, which was down 389.81% from $632000.0 recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $1.7 million during Q3 2023, and its lowest value of -$629000.0 during Q4 2023.
  • Over the past 5 years, Xenon Pharmaceuticals' median Depreciation & Amortization (CF) value was $376000.0 (recorded in 2022), while the average stood at $466526.3.
  • Within the past 5 years, the most significant YoY rise in Xenon Pharmaceuticals' Depreciation & Amortization (CF) was 38435.75% (2023), while the steepest drop was 31250.0% (2023).
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Depreciation & Amortization (CF) stood at $270000.0 in 2021, then grew by 9.63% to $296000.0 in 2022, then crashed by 312.5% to -$629000.0 in 2023, then surged by 205.88% to $666000.0 in 2024, then decreased by 3.75% to $641000.0 in 2025.
  • Its last three reported values are $641000.0 in Q3 2025, $632000.0 for Q2 2025, and $659000.0 during Q1 2025.